Have a personal or library account? Click to login
Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje Cover

Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje

Open Access
|Mar 2026

References

  1. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4. PMID: 31166681.
  2. Moia R, Gaidano G. Prognostication in chronic lymphocytic leukemia. Semin Hematol. 2024 Apr;61(2):83-90. doi: 10.1053/j.seminhematol.2024.02.002. Epub 2024 Mar 1. PMID: 38523019.
  3. Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C., Deambrogi C., Khiabanian H., Serra R., Bertoni F., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121:1403–1412. doi: 10.1182/blood-2012-09-458265.
  4. Pedro Horna, Kathryn E. Pearce, Rhett P. Ketterling, Jess Peterson. Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections, Blood. Volume 134, Supplement 1, 2019. Page 4282. ISSN 0006-4971. https://doi.org/10.1182/blood-2019-129116.
  5. Alexandre Bazinet, Ryan N Rys, Claudia M Wever, Amadou Barry, Celia Green-wood, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, François Mercier, Nathalie Johnson; A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia. Blood 2019; 134 (Supplement_1): 5451. doi: https://doi.org/10.1182/blood-2019-123904.
  6. Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther. 2017 Jan 25; 11:295-304. doi: 10.2147/DDDT.S104869. PMID: 28182141; PMCID: PMC5279834.
  7. Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5. PMID: 29976743; PMCID: PMC6278964.
  8. Ciara L. Freeman, Franck Morschhauser, Laurie Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle-Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron; Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 2015; 126 (24): 2646–2649. doi: https://doi.org/10.1182/blood-2015-09-670802.
  9. Braish J, Cerchione C, Ferrajoli A. An overview of prognostic markers in patients with CLL. Front Oncol. 2024 May 16;14:1371057. doi: 10.3389/fonc.2024.1371057. PMID: 38817892; PMCID: PMC11137234.
  10. Marshall A. Lichtman et al. Williams Manual Of Hematology tenth edition. Part VIII, The Clonal Lymphoid and Plasma Cell Diseases, page 390, 395.
  11. Pirich T, Zwickl-Traxler E, Pecherstorfer M, Singer J. Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study. Oncotarget. 2018 Jul 6;9(52):29944-29956. doi: 10.18632/oncotarget.25714. PMID: 30042825; PMCID: PMC6057460.
  12. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL, Shanafelt TD. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014 Jan;99(1):140-7. doi: 10.3324/haematol.2013.086066. Epub 2013 Aug 2. PMID: 23911703; PMCID: PMC4007929.
  13. Palaian S, Ibrahim MIM, Mishra P et al. Assessment of a Pharmacovigilance Module: An Interventional Study on Knowledge, Attitude, and Practice of Pharmacy Students. J. pharm. bioallied sci. 2021; 13(2):248-255.
  14. Panneerselvam N, Kathirvelu P, Manoharan R. Impact of educational intervention on the knowledge, attitude, and practice of pharmacovigilance among postgraduates of a tertiary care center, Kanchipuram, Tamil Nadu, India. Perspect Clin Res. 2022;13(4):199-204.
DOI: https://doi.org/10.2478/prilozi-2026-0010 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Language: English
Page range: 93 - 100
Published on: Mar 21, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2026 Olivera Gjeorgjieva Janev, Tara Mojsovska, Martin Stojanoski, Marica Pavkovic, Marija Popova Labachevska, Lazar Chadievski, Aleksandra Pivkova Veljanovska, Zlate Stojanoski, Sonja Genadieva Stavrikj, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.